May 2nd 2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
Expanding Statin Treatment Could be Cost-Effective and Prevent ASCVD Events
August 29th 2019A recent study found that expanding statin treatment to those with borderline risk of atherosclerotic cardiovascular disease and high LDL-C levels could prevent ASCVD events and be cost-effective on a population level.
Antiplatelet Therapy Resistance in Diabetes Due to Low Vitamin D
August 16th 2019Severe vitamin D deficiency in people with diabetes treated with dual antiplatelet therapy (DAPT) after an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) is associated with high residual platelet reactivity in patients taking the adenosine-diphosphate (ADP) antagonists ticagrelor or prasugrel, according to an exploratory study epublished on June 7 by Vascular Pharmacology.
Antithrombotic Therapy for the Prevention of Secondary Coronary Artery Disease
August 16th 2019The advent of newer antiplatelet agents and oral anticoagulants has allowed new regimens for secondary prevention of coronary artery disease. When combination therapy is needed, the bleeding risk is particularly pronounced, and the benefits and risks must be balanced for individual patients.
Iron Levels Associated with Lower Cholesterol, Increased Stroke Risk
July 17th 2019Study from investigators in London found that high iron levels were associated with a lower risk of high cholesterol levels and reductions in atherosclerosis, but these same high levels were also associated with increased risk of stroke.